288 related articles for article (PubMed ID: 20051480)
1. Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation.
Pöll F; Lehmann D; Illing S; Ginj M; Jacobs S; Lupp A; Stumm R; Schulz S
Mol Endocrinol; 2010 Feb; 24(2):436-46. PubMed ID: 20051480
[TBL] [Abstract][Full Text] [Related]
2. Structural determinants of agonist-selective signaling at the sst(2A) somatostatin receptor.
Nagel F; Doll C; Pöll F; Kliewer A; Schröder H; Schulz S
Mol Endocrinol; 2011 May; 25(5):859-66. PubMed ID: 21330405
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.
Lesche S; Lehmann D; Nagel F; Schmid HA; Schulz S
J Clin Endocrinol Metab; 2009 Feb; 94(2):654-61. PubMed ID: 19001514
[TBL] [Abstract][Full Text] [Related]
4. Carboxyl-terminal multi-site phosphorylation regulates internalization and desensitization of the human sst2 somatostatin receptor.
Lehmann A; Kliewer A; Schütz D; Nagel F; Stumm R; Schulz S
Mol Cell Endocrinol; 2014 Apr; 387(1-2):44-51. PubMed ID: 24565897
[TBL] [Abstract][Full Text] [Related]
5. Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists.
Kao YJ; Ghosh M; Schonbrunn A
Mol Endocrinol; 2011 Jun; 25(6):1040-54. PubMed ID: 21493671
[TBL] [Abstract][Full Text] [Related]
6. Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes.
Tulipano G; Stumm R; Pfeiffer M; Kreienkamp HJ; Höllt V; Schulz S
J Biol Chem; 2004 May; 279(20):21374-82. PubMed ID: 15001578
[TBL] [Abstract][Full Text] [Related]
7. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
[TBL] [Abstract][Full Text] [Related]
8. A transplantable phosphorylation probe for direct assessment of G protein-coupled receptor activation.
Kliewer A; Mann A; Petrich A; Pöll F; Schulz S
PLoS One; 2012; 7(6):e39458. PubMed ID: 22745760
[TBL] [Abstract][Full Text] [Related]
9. Agonist-biased trafficking of somatostatin receptor 2A in enteric neurons.
Zhao P; Canals M; Murphy JE; Klingler D; Eriksson EM; Pelayo JC; Hardt M; Bunnett NW; Poole DP
J Biol Chem; 2013 Sep; 288(36):25689-25700. PubMed ID: 23913690
[TBL] [Abstract][Full Text] [Related]
10. Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.
Cescato R; Loesch KA; Waser B; Mäcke HR; Rivier JE; Reubi JC; Schonbrunn A
Mol Endocrinol; 2010 Jan; 24(1):240-9. PubMed ID: 19910453
[TBL] [Abstract][Full Text] [Related]
11. Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model.
Waser B; Cescato R; Tamma ML; Maecke HR; Reubi JC
Eur J Pharmacol; 2010 Oct; 644(1-3):257-62. PubMed ID: 20643121
[TBL] [Abstract][Full Text] [Related]
12. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
[TBL] [Abstract][Full Text] [Related]
13. Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary.
Nolan LA; Schmid HA; Levy A
Endocrinology; 2007 Jun; 148(6):2821-7. PubMed ID: 17347306
[TBL] [Abstract][Full Text] [Related]
14. Endothelin-converting enzyme-1 degrades internalized somatostatin-14.
Roosterman D; Kempkes C; Cottrell GS; Padilla BE; Bunnett NW; Turck CW; Steinhoff M
Endocrinology; 2008 May; 149(5):2200-7. PubMed ID: 18276747
[TBL] [Abstract][Full Text] [Related]
15. β-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly.
Gatto F; Feelders R; van der Pas R; Kros JM; Dogan F; van Koetsveld PM; van der Lelij AJ; Neggers SJ; Minuto F; de Herder W; Lamberts SW; Ferone D; Hofland LJ
Endocrinology; 2013 Dec; 154(12):4715-25. PubMed ID: 24169548
[TBL] [Abstract][Full Text] [Related]
16. Pasireotide (SOM230): development, mechanism of action and potential applications.
Schmid HA
Mol Cell Endocrinol; 2008 May; 286(1-2):69-74. PubMed ID: 17977644
[TBL] [Abstract][Full Text] [Related]
17. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
[TBL] [Abstract][Full Text] [Related]
18. The third intracellular loop of the human somatostatin receptor 5 is crucial for arrestin binding and receptor internalization after somatostatin stimulation.
Peverelli E; Mantovani G; Calebiro D; Doni A; Bondioni S; Lania A; Beck-Peccoz P; Spada A
Mol Endocrinol; 2008 Mar; 22(3):676-88. PubMed ID: 18096696
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
[TBL] [Abstract][Full Text] [Related]
20. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.
Hofland LJ; van der Hoek J; Feelders R; van Aken MO; van Koetsveld PM; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; de Herder WW; Beckers A; Lamberts SW
Eur J Endocrinol; 2005 Apr; 152(4):645-54. PubMed ID: 15817922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
